updat compani view februari usd
high grade coverag rate report
today high grade strategi publish latest version usd
high grade coverag rate report report present usd
high grade issuer cover credit research team featur
analyst view current spread level summari comment detail
individu rate find full note thought would
use share healthcare-specif commentari follow page
conveni
particular want highlight month upgrad rate
aet ow uw given recent under-perform made
level look attract peer account significantli lower dollar price
bond upgrad rate uw due
continu success keytruda valuat under-perform peer
manag continu de-emphasi larg scale also
downgrad recommend ow due recent
oper weak spread insid peer hamper rel valu
also want call attent comment addit
separ note publish morn find note
saw last week updat setback stori weaken view
name somewhat stay overweight wider credit valuat
compani commit de-lever overal see cash flow
earn guidanc weaker expect see risk
intermedi de-lever target compani plan near-term debt
reduct ultim leverag target appear place unchang
watch updat capit alloc timelin close june
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
tabl healthcar servic recommend commentari
upgrad rate aet overweight underw eight given
recent signific under-perform hich made level look
attract consid trade account
significantli lower dollar price bond aetna holdco wholli
ow ned non-guarante subsidiari holdco hich structur
senior holdco debt perspect aet insur
gener cash flow time believ aet trade persist
insid due structur senior lower dollar
price current point posit outlook
compani amidst chang landscap healthcar servic
time maintain separ rate aet compar
may decid absorb rate time depend
disclosur made compani risk rate includ oper
setback lack focu name caus investor
prefer manag care name
maintain overweight recommend ci continu
view esrx merger posit creat integr model
posit compani ell evolv manag landscap
importantli de-lever continu primari focu evidenc
compani expect use cash flow plan
debt repay compani explicit commentari top capit
deploy prioriti acceler debt repay see
low er expect overal cash flow due earli termin
modest neg still see reason ci achiev
de-lever goal upper debt-to-cap year assum
reason amount book valu growth net recent
disclosur see credit still solid posit believ time
ci trade insid think name compress
look esrx bond ill benefit guarante ci parent
 believ fall-aw ay provis leav long esrx bond
persist trade behind new ci bond risk rate includ
advers court rule litig environment chang leav
pbm manag organ disadvantag aggress
balanc sheet manag expect
compani recent weak guidanc clear setback
introduc new variabl credit stay overweight bond
continu trade wide long-term driver credit remain place
compani remain commit leverag target overal much
challeng inher guidanc address importantli
reflect integr issu aet affect main valu driver
transact see cash flow earn guidanc
 eaker ere expect see risk intermedi de-lever
target compani plan near-term debt reduct ultim
leverag target appear place unchang long
continu use cash flow debt reduct
acceler capit return plan sharehold believ rate agenc
 ill patient time addit oper eak put
compani behind de-lever goal chang financi
policy/capit alloc time primari risk rate
tabl healthcar servic recommend commentari cont
laboratori corp
hold overweight recommend lh valuat remain
 ider end reason rang view despit recent
setback lab overal note posit compani
delev substanti sinc covanc deal pay debt
high end long-term leverag target rang
 expect much de-lever go forw ard addit oper
trend though gener weak lab side support
covanc busi good enough credit importantli
recommend valuat remain wide hen compar peer
risk rate includ aggress ith compani say
 ould continu look attract opportun given balanc sheet
strength favor debt matur schedul well eak come
covanc busi sector disrupt leav independ lab
disadvantag
continu hold neutral rate wide valuat off-set
industri pressur compani continu expect earn
pressur go forw ard see compani expos specialti drug
price pressur continu scrutini surround opioid believ
event risk merit monitor given compani express interest
execut vari size past though histor manag
commentari around strong balanc sheet need invest
grade give us comfort increas scrutini pharmaceut
suppli chain also leav compani suscept chang
environ similar distributor like uncertainti
hold valuat back time howev compani state
believ defend valu proposit adjust contract
time risk rate upsid includ turnaround industri price
increas balanc sheet conservat downsid larg
leverag transact stretch balanc sheet government
regul advers affect compani
maintain neutral recommend ith uncertain busi
environ opioid risk off-set current spread level oper
setback convers chang pharma suppli chain
ad doubt futur result post last year acquisit see
compani cushion current rate diminish ultim
expect compani ill adapt environ anticip
out-performance near term given industri overhang ill take time
 ork system said expect firm ill manag
balanc sheet conserv adjust current environ
 posit note follow ing review busi capit
deploy strategi compani expect futur capit deploy ill
disciplin said want maintain healthi balanc sheet risk
dow nside rate includ continu weak drug price trend
chang model leav distributor disadvantag advers
opioid develop hile risk upsid includ potenti turnaround
price trend could substanti boost profit balanc sheet
hold neutral rate amidst chang environ
compani show strong oper result
 believ expand partnership ould view
credit posit evolv manag landscap howev
manag express desir maintain financi strateg flexibl
continu evalu strateg acquisit build capabl
particularli primari care model evolv toward integr
offer valuat sit insid ci hich limit us
posit view risk rate upsid includ sustain
oper perform conjunct conserv balanc sheet
manag market revisit possibl full acquisit
higher rate peer risk downsid includ pursuit larg debt-
tabl healthcar servic recommend commentari cont
maintain neutral rate compani continu face
oper headwind amid brand gener drug price trend
expect margin headwind europ ill take time turn around
 look forw ard expect ill stay import part healthcar
suppli chain see uncertainti busi risk limit spread
out-performance time furthermor concern opioid
epidem continu weigh distributor expect fine
 ill materi exceed cash gener headlin risk remain risk
rate includ posit turnaround environ financi
conservat expect hile neg risk includ acceler
industri competit continu weak price environ
healthcar reform advers affect distributor potenti
larg
downgrad recommend neutral spread
held rel well recent oper weak
continu show conserv tone relat balanc sheet
capit manag primari driver prior recommend
someth expect continu spread insid lh
 longer see signific valu bond underli
challeng busi emerg risk rate downsid
includ addit oper challeng sharehold pressur
aggress ith balanc sheet recent under-perform sizabl
debt-financ hile risk upsid includ conserv
balanc sheet manag better oper result expect
see best posit compani manag space
 view compani diversif unregul cash flow
strong credit posit firm diversifi ithin medic
benefit busi wit strong result optum servic
offer addit compani debt-to-capit stand high-
zone strong cash flow capit growth enabl
delev faster peer note higher leverag metric
less issu rel peer given larg servic busi
 comfort ith exposur overal diversifi
busi model appear insul headlin swirl around
greater manag space current valuat ell insid peer
hold us back posit view nside risk rate includ
slow ed pace de-lever well oper setback core
insur servic busi given on-going industri debat
pharma suppli chain convers risk upsid would strong result
across busi line addit de-lever
maintain uw rate ith bond trade well insid peer ci
expect market ill pay attent compani
tendenc run balanc sheet aggress peer well
outstand legal challeng ci could lead cash outflow
compani also note rel new ceo transit sourc
uncertainti term futur strateg direct increas share
repurchas plan high leverag open uncertain
manag environ leav us cautiou expect ill
eventu pay break fee ci note upsid
potenti court rule favor demand payment
everyth taken togeth pair valuat still tight
peer believ level under-perform believ ci
trade insid risk rate includ potenti shift
tow ard conserv financi polici improv oper perform
tabl pharma/med devic recommend commentari
hold overw eight view given hat view unjustifi
concern larg recent credit-friendli manag commentari
action compani ill like remain activ
focus exist therapeut area scientif deal ell
partnership augment pipelin believ transact ill
small natur materi chang credit profil compani
especi consid larg amount cash balanc sheet thu
 see deal manag ithin strong credit profil stabl
hiv contribut despit recent clinic trial setback challeng
hcv segment past year though compani say trend
becom predict line ith expect primari
risk rate potenti larger acquisit lead rate
pressur given eak trend hcv diminish cushion
current rate addit increment eaken hiv result could
maintain neutral rate see ide spread fairli
compens long-term risk substanti compon profit come
singl product humira repres sale hich ill face
gener competit late us period time prior
gener launch ill give compani time abil use current
cash flow prepar event bring new product market er
believ percept market compani quick
priorit sharehold bondhold reason name
continu trade rel ide see name ide rel
fair valu posit bia current level believ order
bond meaning outperform ould need reduc debt
otherw ise show action support credit near term risk
rate upsid includ firm keep activ limit
meaning reduc overal level leverag time hile risk
dow nside includ larg debt-financ develop eaken
maintain neutral rate follow ing recent iden
feel current spread fairli price versu peer overal believ
compani continu make progress tow ard stabil continu
say right thing credit perspect includ comment ill
target net leverag end estim compani ill
reduc debt net ye level achiev goal
ever follow ing prevent us posit view activist
interest pick name hich increas uncertainti believ
compani reason consid term short capit structur
 expect debt buyback ill continu go forw ard someth
larg drove name risk dow nside includ return
aggress financi polici eak underli result core
busi industri continu come scrutini busi
practic price risk upsid includ abl execut asset
sale along ith broader debt reduct current expect
neutral view driven good oper result fair spread
level off-set open focu potenti larg sharehold
return see averag event risk believ
manag ill continu use larg cash balanc primarili
 share repurchas ith compani say remain
focus deal size key therapeut area recent pace
repurchas reason guid futur view
compani view capit structur balanc posit equiti
holder debt holder separ find less posit
name thank price uncertainti top drug enbrel given histori
revenu grow th driven price fda recent focu support
biosimilar adopt coupl ith recent approv biosimilar epogen
risk rate includ potenti substanti ith compani
explicitli rule mega merger convers balanc sheet conservat
could lead de-lever slow er pace issuanc
tabl pharma/med devic recommend commentari
continu rate neutral tight valuat offset continu
posit view credit belief ill upgrad rate
back ig leverag end recent quarter
initi leverag bcr transact rang strong cash
flow post-deal also note manag consist reaffirm
expect de-lev decemb compani paid
debt previous guid given current
valuat see valu year part curv risk
rate downsid includ busi setback could lead rate
pressur exposur market beta sentiment risk upsid
includ potenti compani pursu divestitur alter financ
plan accordingli return invest grade rate sooner
upgrad rate neutral uw given keytruda
continu success stabl oper therapeut categori
valuat under-perform peer recent past addit
compar mani peer manag continu de-emphas large-
scale focus deal believ value-ad
minimum disrupt on-going scientif effort light see risk
larg debt-financ acquisit low compar other space
find hard expect materi iden near-term note
compani issu debt usd sinc earli ould much
rather ait new issuanc exist issu risk
upsid includ addit posit pipelin result along limit deal
make strengthen compani alreadi high-qual balanc sheet
risk downsid includ larg debt-financ signific financi
neutral rate despit compani wide valuat
rest space compani undergo broad strateg
review look everyth expect uncertainti risk
credit certain altern keep spread rel wide
clariti achiev major issu credit investor mani
exist credit commit previous expect
year-end long term invest grade debt paydown
next year revolv around statu quo compani note
commit take strateg review account state
someth come committe decis mayb there
adjust outsid strateg review underli earn
 eak major pipelin opportun delay though recent
gadvair approv posit develop
collus probe contribut uncertainti risk rate upsid
includ turnaround gener market conserv balanc
sheet manag expect includ resolv strateg review
 ithout credit deterior risk downsid includ strateg
review decis benefit sharehold expens debthold
challeng busi trend advers develop collus
tabl pharma/med devic recommend commentari cont
maintain neutral view wake recent oper
challeng compani plan separ rx busi recent
neg surpris regard compani tax assess ireland even
though view rate safe believ compani ant
maintain ig level mani neg uncertainti like keep
spread wide level notabl tax issu like resolv
extend period time ith sale spin rx busi
compani decid util proce like drive credit near
term result skew neg fundament
long-term basi valuat well ide ig healthcar
name off-set much neg risk rate downsid
includ potenti eak oper result structur separ
rx busi leav creditor disadvantag weaken
compani ig commit risk upsid includ potenti better
oper result continu basi conserv balanc sheet
manag well quick resolut irish tax author
hold neutral rate given recent solid oper result
organ growth strong well on-going de-lever leverag
dow off-set tight valuat compani made signific
progress de-lever expect anoth debt paydown
year though allow compani focu activ
especi recent sale anatom patholog busi
compani said provid firepow er deploy
ever compani track record give investor level
confid risk upsid includ balanc sheet conservat
rapid de-lever expect downsid realiz
fear greater lever activ via oper setback
continu hold neutral rate steadi oper
perform fair balanc sheet off-set current valuat
believ appropri reflect dynam current sit tight end
fair valu also expect rate stay leverag
 ill remain zone guid manag view firm
oper posit thank lead posit credit-friendli anim
health industri consist oper result last year
risk downsid includ potenti firm significantli
increas leverag fund major transact though note abil
pursu large-scal deal sector limit anti-trust concern
market share manag indic desir pursu risk
upsid includ continu oper strength conserv balanc
tabl pharma/med devic recommend commentari cont
 morgan publish februari usd high grade coverag rate report
hold uw rate given recent comment compani
hint aggress larger size potenti new vertic and/or
sharehold return activ fundament stori remain gener fair
tight valuat plan relev balanc sheet
time primari item hold back view relev compani
talk get net leverag time someth would
requir increment debt current level achiev
 manag express willing past pursu deal
market cap recent note could open
larger deal compani also said absenc deal
balanc sheet buy aggress share back risk rate
includ mute pace balanc sheet relev
prefer market devic name healthcar sector
remain underw eight light tight valuat compar
peer recent pipelin setback threat leverag
lack product diversif hich ill like lead relianc
compani riskier-than-norm pipelin oper result remain fair
leverag remain low concern compani relianc ms
drug addit manag shift aw ay histor
conserv strategi follow ing strateg review recent note
open later-stag deal given financ capac risk
rate includ conserv balanc sheet manag
expect potenti take-over larger higher rate firm seen
press report
view best capit strongest compani sector
 ith substanti diversif across consum medic devic pharma
market ever compani trade tight level present
limit upsid view focus compani remain
open acquisit specif medic devic talc litig
repres unpredict risk like take extend period time
play long-term expect compani ill face increas
call split lever time expect gain
much traction risk rate includ potenti firm undertak
signific debt reduct gener flight qualiti event eak
analyst certif author name within report research analyst unless otherwis specifi research analyst
denot ac cover report certifi multipl research analyst primarili respons report
research analyst denot ac cover within document individu certifi respect secur issuer
research analyst cover research view express report accur reflect person view
subject secur issuer part research analyst compens
directli indirectli relat specif recommend view express research analyst report korea-
base research analyst list front cover also certifi per kofia requir analysi made good faith
view reflect opinion without undu influenc intervent
